Deans' stroke musings: Interleukin-1 as a pharmacological target in acute brain injury

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, June 15, 2015

Interleukin-1 as a pharmacological target in acute brain injury

What does your doctor have say about this? I've written 8 posts on this already, so your doctor has NO excuse for not knowing about this.

Interleukin-1 as a pharmacological target in acute brain injury

David Brough,
Nancy J Rothwell^* and
Stuart M Allan

DOI: 10.1113/EP085135

Issue

Experimental Physiology

Accepted Article (Accepted, unedited articles published online and citable. The final edited and typeset version of record will appear in future.)

Additional Information(Show All)

Author Information Publication History

This is an Accepted Article that has been peer-reviewed and approved for publication in the Experimental Physiology, but has yet to undergo copy-editing and proof correction. Please cite this article as an ‘Accepted Article’; doi: 10.1113/EP085135.

Cited By

Get PDF (361K)

Acute brain injury is one of the leading causes of mortality and disability worldwide. Despite this, treatments for acute brain injuries are limited and there remains a massive unmet clinical need. Inflammation has emerged as a major contributor to non-communicable diseases and there is now substantial and growing evidence that inflammation, driven by the cytokine interleukin-1 (IL-1), worsens acute brain injury. IL-1 is regulated by large multi-molecular complexes called inflammasomes. Here we discuss the latest research on the regulation of inflammasomes and IL-1 in the brain, pre-clinical efforts to establish the IL-1 system as a therapeutic target, and the promise of recent and future clinical studies of blocking IL-1 action for the treatment of brain injury.